# Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

> **NCT06280482** · PHASE1 · RECRUITING · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 15 (estimated)

## Conditions studied

- Smooth Muscle Dysfunction Syndrome (SMDS)

## Interventions

- **DRUG:** Nicotinamide riboside (NR)

## Key facts

- **NCT ID:** NCT06280482
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-06
- **Primary completion:** 2027-07-25
- **Final completion:** 2027-07-25
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06280482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06280482, "Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06280482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*